Pleurisy Market Overview
Pleurisy Market Size was valued at USD 1.73 Billion in 2023. The Pleurisy industry is projected to grow from USD 1.83 Billion in 2024 to USD 3.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.94% during the forecast period (2024 - 2032).
Pleurisy is the inflammation of the membrane known as pleura that surrounds the lungs inside the chest cavity. People suffering with pleurisy can experience chest pain while breathing. This disease is characterized by symptoms such as shortness of breath, cough, fever, and weight loss. Pneumonia, pulmonary embolism, autoimmune disorder, lung cancer, heart surgery, pancreatitis, chest trauma, and asbestosis are the diseases which cause pleurisy, thus, rising in population affected with these disease are the leading factor for the growth of global pleurisy market. According to a report published by the World Cancer Research Fund International, in 2015, about 58% of lung cancer cases occurred in the developing countries. In a similar report by Centers for Disease Control and Prevention (CDC), in 2017, lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States.
There are various causes responsible for this condition, such as rising aging population, unhealthy diet, low physical activities, etc. According to a research, smoking increases the possibility of lung cancer; more than 60% of the global population smokes, this has increased the risk of lung cancer and contributed to the growth of the market. Moreover, advancing technology in medical devices is adding fuel to the growth of the market. Furthermore, increasing government support for the developing countries also drives the market growth. However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.
Pleurisy Market Segment Insights
The pleurisy global market is segmented on the basis of diagnosis devices, treatment, and by end user. On the basis of the diagnosis devices, it is segmented into thoracentesis, video-assisted thoracic surgery, imaging devices, blood test, and others. Furthermore, imaging devices are segmented as computed tomography, magnetic resonance imaging, ultrasound, and others.
On the basis of the treatment, it is segmented into antibiotics, antifungals, blood thinners, nonsteroidal anti-inflammatory drugs, and others. On the basis of end user, it is segmented into hospital, clinics, diagnostics laboratories, and others.
Pleurisy Market Regional Analysis
The Americas dominate the global pleurisy market owing to the rising prevalence of disease such as autoimmune disorders, lung cancer, heart surgery, pancreatitis, chest trauma. Furthermore increasing government support for research & development and high healthcare spending have fuelled the growth of the market in this region. According to a report published by the Centers for Disease Control and Prevention (CDC), in 2014, around 215,951 people in the United States were diagnosed with lung cancer, including 113,326 men and 102,625 women. Also around 155,526 people in the United States died from lung cancer, including 84,859 men and 70,667 women.
Europe holds the second position in the global pleurisy market owing to the government support for research & development and availability of funds for research. Moreover, people of this region are more healthcare awareness. This is expected to continue to drive the European market over the forecasted period.
Asia Pacific is the fastest growing pleurisy market owing to the high presence of patient with chronic disease. Although rapidly developing healthcare technology, increasing demand for new treatment methods in countries like India and China is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare provide the opportunity for the market players to fill the gap between demand and supply and maximize the profits.
On the other hand, in the Middle East and Africa, hold the least market due to low research and development activities and poor healthcare infrastructure.
Pleurisy Market Key Players
Some of the key players in this market are:
- Scanlan International, Inc. (U.S.)
- Sontec Instruments (U.S.)
- Pilling Surgical Inc. (U.S.)
- Integra LifeSciences Corporation (U.S.)
- Olympus Corporation (Japan)
- Delacroix-Chevalier (France)
- Myra & Co. (India)
- Wexler Surgical (Texas)
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience
- Medical Devices Manufacturers
- Government Research Laboratories
- Research and Development (R&D) Companies
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
- Medical Research Laboratories
Report Attribute/Metric |
Details |
Market Size |
3.23 Billion |
CAGR |
6.94% |
Base Year |
2023 |
Forecast Period |
2024-2032 |
Historical Data |
2020 |
Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Diagnosis devices, Treatment and End user |
Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors |
Scanlan International, Inc. (U.S.), Sontec Instruments (U.S.), Pilling Surgical Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Olympus Corporation (Japan), Delacroix-Chevalier (France), Myra & Co. (India), Wexler Surgical (Texas) |
Key Market Opportunities |
Quality Devices Manufacturer |
Key Market Drivers |
Rising aging population· Unhealthy diet· Low physical activities |
Pleurisy Market Highlights:
Frequently Asked Questions (FAQ) :
There is a membrane called pleura inside the chest cavity that surrounds the lungs. Any type of inflammation in it is known as pleurisy.
Pleurisy market CAGR during the forecast period would be 6.8% during the forecast period.
Pleurisy market players are Scanlan International, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sontec Instruments (U.S.), Delacroix-Chevalier (France), Olympus Corporation (Japan), Wexler Surgical (Texas), Myra & Co. (India), Pilling Surgical Inc. (U.S.), and others.
The Americas would lead the global pleurisy market platform.
The Asia Pacific would garner the maximum CAGR among all pleurisy market regions.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report